Japan Benign Prostatic Hyperplasia Therapeutics Market was valued at USD 0.9 Billion in 2022 and is projected to reach USD 1.4 Billion by 2030, growing at a CAGR of 5.4% from 2024 to 2030.
Benign Prostatic Hyperplasia Therapeutics Market in Japan: Applications in Drug Therapy
The market for benign prostatic hyperplasia (BPH) therapeutics in Japan is significantly driven by the application of drug therapy. BPH is a common condition among aging males, characterized by an enlarged prostate gland that can cause urinary difficulties. The primary aim of drug therapy in treating BPH is to alleviate these symptoms and improve the quality of life for patients. Two main classes of medications are used: alpha blockers and 5-alpha-reductase inhibitors. Alpha blockers, such as tamsulosin and alfuzosin, work by relaxing the muscles in the prostate and bladder neck to facilitate easier urination. On the other hand, 5-alpha-reductase inhibitors, including finasteride and dutasteride, reduce the size of the prostate by inhibiting hormonal changes that cause growth. The strategic application of these drugs has proven effective in managing BPH symptoms and reducing the need for surgical intervention, making them a cornerstone of BPH treatment in Japan.
Surgical Therapy Applications in Japan’s BPH Market
While drug therapy remains the first line of treatment for BPH, surgical interventions play a crucial role when medications fail to provide adequate relief. Surgical therapy options include minimally invasive procedures and more traditional surgeries like transurethral resection of the prostate (TURP). TURP is considered the gold standard and involves the removal of prostate tissue to relieve obstruction. Minimally invasive techniques, such as laser therapy and transurethral microwave therapy, have gained popularity due to their reduced recovery times and lower risk of complications. These procedures use advanced technologies to precisely target and remove excess prostate tissue. The choice of surgical treatment depends on the severity of symptoms, the size of the prostate, and the patient’s overall health. In Japan, the application of these surgical therapies is supported by the availability of cutting-edge medical equipment and skilled healthcare professionals, contributing to better outcomes for patients.
Get an In-Depth Research Analysis of the Japan Benign Prostatic Hyperplasia Therapeutics Market Size And Forecast [2025-2032]
Who are the largest Japan manufacturers in the Benign Prostatic Hyperplasia Therapeutics industry?
- Abbott Laboratories
- Allergan plc
- Astellas Pharma
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co.
- Pfizer
- Sanofi
- Teva Pharmaceutical Industries Limited
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Benign Prostatic Hyperplasia Therapeutics Market Size And Forecast [2025-2032]
What are the factors driving the growth of the Japan Benign Prostatic Hyperplasia Therapeutics Market?
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Benign Prostatic Hyperplasia Therapeutics Market
- Mono drug therapy
- Combination drug therapy
What are the types of Benign Prostatic Hyperplasia Therapeutics available in the Market?
Based on Types the Market is categorized into Below types that held the largest Benign Prostatic Hyperplasia Therapeutics market share In 2023.
- Alpha blocker
- 5-Alpha reductase inhibitor
- Phosphodiesterase-5 inhibitor
- Others
Which regions are leading the Japan Benign Prostatic Hyperplasia Therapeutics Market?
- Japan (United States, Japan and Mexico)
- Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil, Argentina, Columbia, etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Benign Prostatic Hyperplasia Therapeutics Market Research Analysis
Detailed TOC of Japan Benign Prostatic Hyperplasia Therapeutics Market Research Report, 2024-2032
1. Introduction of the Japan Benign Prostatic Hyperplasia Therapeutics Market
- Overview of the Market
- Scope of Report
- Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
- Data Mining
- Validation
- Primary Interviews
- List of Data Sources
4. Japan Benign Prostatic Hyperplasia Therapeutics Market Outlook
- Overview
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Porters Five Force Model
- Value Chain Analysis
5. Japan Benign Prostatic Hyperplasia Therapeutics Market, By Type
6. Japan Benign Prostatic Hyperplasia Therapeutics Market, By Application
7. Japan Benign Prostatic Hyperplasia Therapeutics Market, By Geography
- Japan
- Europe
- Asia Pacific
- Rest of the World
8. Japan Benign Prostatic Hyperplasia Therapeutics Market Competitive Landscape
- Overview
- Company Market Ranking
- Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Japan Research and Consulting firm servicing over 5000+ Japan clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
